^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Renal Cell Carcinoma

    Related cancers:
    1d
    CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Cdactin-O (CBM588)
    1d
    A Phase 1b study evaluating the safety and preliminary efficacy of AXA-042 monotherapy in patients with advanced solid tumours. (ACTRN12626000289314)
    P1, N=31, Recruiting, Axelia Oncology Pty Ltd
    New P1 trial
    |
    AXA-042
    1d
    XmAb819-01: Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=307, Recruiting, Xencor, Inc. | N=95 --> 307 | Trial completion date: Nov 2027 --> Dec 2028 | Trial primary completion date: Feb 2026 --> Feb 2027
    Enrollment change • Trial completion date • Trial primary completion date
    1d
    The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    1d
    E2810: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery (clinicaltrials.gov)
    P3, N=129, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    pazopanib
    2d
    Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial (clinicaltrials.gov)
    P2, N=200, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    2d
    CALySSEY: CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors (clinicaltrials.gov)
    P1, N=88, Not yet recruiting, Baylor College of Medicine | Initiation date: Jan 2026 --> Jun 2026
    Trial initiation date
    2d
    (BLOOM): Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy (clinicaltrials.gov)
    P1/2, N=55, Not yet recruiting, University of Chicago | Initiation date: Jan 2026 --> Dec 2026
    Trial initiation date
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    2d
    Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P1/2, N=47, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    mTOR (Mechanistic target of rapamycin kinase)
    |
    Jingzhuda (entinostat) • Proleukin (aldesleukin)
    2d
    LIAM Mc: Linking In With Advice and Supports for Men Impacted by Metastatic Cancer (clinicaltrials.gov)
    P=N/A, N=72, Active, not recruiting, University College Cork | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> Mar 2026
    Enrollment closed • Trial primary completion date
    2d
    Ablative Radiotherapy to Restrain Every Metastasis Safely Treatable (ARREST-2): A Randomized Phase II/III Trial (clinicaltrials.gov)
    P=N/A, N=138, Recruiting, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Trial completion date: Jan 2027 --> Jan 2034 | Trial primary completion date: Jan 2026 --> Jan 2034
    Trial completion date • Trial primary completion date
    2d
    A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) (clinicaltrials.gov)
    P1/2, N=234, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • pumitamig (BNT327)